Serotonin News and Research

Latest Serotonin News and Research

Study looks at effects of antipsychotic drugs on two brain receptors linked to schizophrenia

Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.

24 Nov 2011

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

The Therapeutic Goods Administration (TGA), Australia's regulatory body for therapeutic products, granted Pierre Fabre Médicament's milnacipran market authorisation for the treatment of fibromyalgia.

21 Nov 2011

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

Alcohol can readily decrease function of women's serotonin system

After only four years of problem drinking, a significant decrease in the function of the serotonin system in women's brains can be seen. This is the system that regulates such functions as impulse control and mood. It takes 12 years before a corresponding decrease is seen in men.

16 Nov 2011

Research offers clues that may explain behavior, mood changes in stress-related disorders

Research released today uses the latest genetic tools to explore how stress alters brain function, leading to anxiety, depression, and other stress-related mood disorders.

16 Nov 2011

Combination of antipsychotic and antidepressant drugs may increase risk of CV mortality

People taking anti-psychotic drugs and anti-depressant drugs have a much higher risk of dying during an acute coronary event of a fatal arrhythmia than the rest of the population, finds a Finnish study published in the European Heart Journal.

16 Nov 2011

Multiple medication use may increase severity of erectile dysfunction

The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International.

15 Nov 2011

Health benefits of nut consumption

A recent scientific study has revealed the relationship between nut consumption and a high level of serotonin metabolites (an important neurotransmitter) in patients with metabolic syndrome, who are at high risk of cardiovascular disease.

11 Nov 2011

A woman’s brain can get damaged faster with alcohol abuse: Study

A latest study has shown that female alcoholics suffer damage to the part of their brain that controls moods, impulses and sleep three times faster than their male counterparts.

10 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Psychotherapy could have diverse cerebral effects depending on certain genes

Problems like anxiety and depression are caused by psychological and environmental factors, and are known to be influenced by genetic proclivities. However, it is still not clear how each factor affects the brain's functions to induce anxious and depressive symptoms.

4 Nov 2011

Amphetamine use in adolescence can affect brain chemistry and behaviour

Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behaviour, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models conducted by McGill University Health Centre (MUHC) researcher Dr. Gabriella Gobbi and her colleagues.

4 Nov 2011

Escitalopram reduces pain severity, interference in opioid-dependent patients

In what is believed to be the first study of its kind to demonstrate an association between the antidepressant escitalopram and improved general pain, researchers from Boston University School of Medicine (BUSM), have found that opioid-dependent patients treated with escitalopram experienced meaningful reductions in pain severity and pain interference during the first three months of therapy.

4 Nov 2011

Link between eating nuts and higher levels of serotonin in MetS patients

For the first time, scientists report a link between eating nuts and higher levels of serotonin in the bodies of patients with metabolic syndrome (MetS), who are at high risk for heart disease.

3 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

HHWC medical doctors provide insight into depression

A staggering 230 million antidepressant prescriptions are filled each year. Yet the face of depression does not always fit the mold: a successful career, loving spouse, wonderful children, seemingly good health and finances. From the outside life appears perfect, so why are Americans depressed?

15 Oct 2011

AiC: Health Research receives U.S. Army grant for neuroimaging studies of human performance

The Arlington Innovation Center: Health Research (AiC: Health Research), of Virginia Tech's National Capital Region, has been awarded a $1.5 million cooperative research and development agreement from the U.S. Army for neuroimaging studies of human performance.

14 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011